GlassScriptPhysician profile
Casey Oliver Hurst
NPI 1588892814
$10,222.32
in general payments reported to CMS, 2019-2025
54 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $441 · 2021: $1,834 · 2022: $1,816 · 2023: $2,024 · 2024: $1,851 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,253.88 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $844.06 | 2020-2025 | |
| Lilly USA, LLC | $800.49 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $754.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $728.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $539.92 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.31 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $457.69 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.13 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $404.50 | 2021-2025 | |
| Abbott Laboratories | $384.93 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Dexcom, INC. | $335.31 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $227.08 | 2019-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $206.01 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $196.64 | 2019-2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.